MedPath

AstraZeneca

AstraZeneca logo
🇬🇧United Kingdom
Ownership
Public
Employees
89.9K
Market Cap
$270.3B
Website
http://www.astrazeneca.co.uk
Introduction

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials
Related News

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

Phase 1
Completed
Conditions
Cystic Fibrosis
Interventions
Drug: AZD5634 for infusion
Drug: AZD5634 for inhalation
Other: Placebo
First Posted Date
2016-02-10
Last Posted Date
2018-11-05
Lead Sponsor
AstraZeneca
Target Recruit Count
63
Registration Number
NCT02679729
Locations
🇺🇸

Research Site, Baltimore, Maryland, United States

Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERD

Phase 3
Completed
Conditions
Gastroesophageal Reflux
Interventions
First Posted Date
2016-02-02
Last Posted Date
2016-02-02
Lead Sponsor
AstraZeneca
Target Recruit Count
877
Registration Number
NCT02670642
Locations
🇩🇪

Gemeinschaftspraxis, Köln, Germany

🇩🇪

Frankenwaldklinik, Kronach, Germany

🇦🇹

Hanusch Hospital, Wien, Austria

and more 57 locations

A Study of Lanabecestat (LY3314814) in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2016-01-26
Last Posted Date
2019-11-01
Lead Sponsor
AstraZeneca
Target Recruit Count
18
Registration Number
NCT02663128

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Phase 1
Completed
Conditions
Carcinoma, Squamous Cell of Head and Neck
Stomach Neoplasms
Ovarian Neoplasms
Carcinoma, Pancreatic Ductal
Esophageal Squamous Cell Carcinoma
Triple Negative Breast Neoplasms
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Esophagogastric Junction Neoplasms
Small Cell Lung Carcinoma
Interventions
Biological: durvalumab
Biological: tremelimumab
First Posted Date
2016-01-18
Last Posted Date
2020-08-20
Lead Sponsor
AstraZeneca
Target Recruit Count
32
Registration Number
NCT02658214
Locations
🇰🇷

Research Site, Seoul, Korea, Republic of

A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2016-01-12
Last Posted Date
2018-02-23
Lead Sponsor
AstraZeneca
Target Recruit Count
15
Registration Number
NCT02653872
Locations
🇬🇧

Research Site, London, United Kingdom

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

Phase 1
Completed
Conditions
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Drug: AZD7594 Solution for infusion (150 μg intravenous formulation)
Drug: AZD7594 Oral suspension (1200 μg oral formulation)
Drug: AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)
Drug: AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)
Drug: AZD7594 Pressurized inhalation suspension (400 μg) by pMDI
First Posted Date
2016-01-07
Last Posted Date
2017-06-15
Lead Sponsor
AstraZeneca
Target Recruit Count
30
Registration Number
NCT02648438
Locations
🇺🇸

Research Site, Baltimore, Maryland, United States

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Phase 1
Completed
Conditions
Chronic Obstructive Pulmonary Disease COPD
Asthma
Interventions
Drug: AZD7594 inhalation powder (200 μg)
Drug: AZD7594 inhalation powder (400 μg)
Drug: AZD7594 pressurized inhalation suspension (200 μg)
Drug: AZD7594 placebo inhalation powder
Drug: AZD7594 placebo pressurized inhalation suspension
First Posted Date
2016-01-01
Last Posted Date
2018-02-19
Lead Sponsor
AstraZeneca
Target Recruit Count
27
Registration Number
NCT02645253
Locations
🇺🇸

Research Site, Glendale, California, United States

Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase

Phase 1
Completed
Conditions
Solid Malignancies
Interventions
Drug: [14C]AZD2014
Drug: Multiple dose AZD2014
First Posted Date
2015-12-29
Last Posted Date
2019-04-22
Lead Sponsor
AstraZeneca
Target Recruit Count
4
Registration Number
NCT02640755
Locations
🇬🇧

Research Site, Manchester, United Kingdom

Asthma Control, Quality of Life and Emotional Feelings in a Real Life Setting

Completed
Conditions
Asthma
First Posted Date
2015-12-29
Last Posted Date
2017-10-25
Lead Sponsor
AstraZeneca
Target Recruit Count
1232
Registration Number
NCT02640742
Locations
🇯🇵

Fukuokaken Saiseikai Futsukaichi Hospital, Chikushino, Fukuoka, Japan

🇯🇵

Japan Community Health Care Organization Kurume General Hospital, Kurume, Fukuoka, Japan

🇯🇵

Omuta Tenryo Hospital, Omuta, Fukuoka, Japan

and more 54 locations

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Phase 1
Completed
Conditions
Bioequivalence
Fixed Dose Combination Tablets
Healthy Male and Female Subjects
Interventions
Drug: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)
Drug: dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)
Drug: dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)
Drug: dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
First Posted Date
2015-12-22
Last Posted Date
2018-03-13
Lead Sponsor
AstraZeneca
Target Recruit Count
80
Registration Number
NCT02637037
Locations
🇺🇸

Research Site, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy